Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

As telecom operators face mounting pressure to modernize aging infrastructure while maintaining service continuity, IPLOOK delivers a cost-efficient evolution blueprint that bridges legacy 2G/3G ...

Market Dojo, a leader in eSourcing solutions, has partnered with Focal Point, a pioneer in intake and orchestration, to deliver an integrated platform that streamlines procurement success. A Seamless ...

U.S. President Donald Trump threatened to impose tariffs of around 25 percent on pharmaceutical imports on Tuesday, raising ...

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...